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Delphi studyIntroduction: This study aimed to develop and undertake a preliminary validation of a French Survey
Questionnaire for the Determinants of HPV Vaccine Hesitancy (FSQD-HPVH).
Methods: We undertook an electronic-based Delphi consultation among a panel of Francophone experts
in two rounds. Round 1 consisted of the assessment of a structured questionnaire comprising of three
parts ((i) Contextual influences, (ii) Individual and group influences, and (iii) Vaccine/vaccination-
specific issues), in line with the WHO Strategic Advisory Group of Experts (SAGE) Vaccine Hesitancy
(VH) Model of Determinants. Items included in this questionnaire were based on a literature review.
Definitions of the factors included in the SAGE model were provided in the questionnaire. The panel of
experts was asked to score each item using a 3-point Likert scale, in which 1 meant ‘‘Essential”, 2
‘‘Useful but not essential”, and 3 ‘‘Not necessary”. The panel was also invited to comment on the clarity/
comprehension of the questions and suggest reformulations/additional items. Lawshe’s Content Validity
Ratio (CVR) was computed to assess the level of consensus for each statement. Only items upon which
agreement was not reached in Round 1 (CVR < 0.6) and newly proposed items were submitted for eval-
uation in Round 2, using the same procedure.
Results: Fifteen experts completed the two rounds. Of 83 items evaluated in Round 1, 35 (42%) had a
CVR  0.6 and were accepted without modification. In Round 2, 66 items were submitted to the same
panel and consensus was reached for 22 (33%) items using the threshold of 0.6. The final FSQD-HPVH ver-
sion includes 57 items.
Conclusion: This study developed a survey instrument for the evaluation of HPV VH in France with good
content validity. It will be used to assess the determinants of HPV VH, the first step towards an evidence-
based approach to improving HPV vaccination rates in France.
 2020 Elsevier Ltd. All rights reserved.1. Introduction
In a global study conducted by the Wellcome Trust in over 140
countries, France was identified as the country with the lowestconfidence in vaccine safety with ‘‘one in three people disagree
that vaccines are safe” [1]. In this context, vaccination to prevent
human papillomavirus (HPV) infection, the most common sexually
transmitted infection (STI) worldwide and the etiological agent of a
range of conditions including anogenital and oropharyngeal can-
cers, is one of the most challenging in France.
In 2019, HPV vaccination in France is recommended for all girls
aged 11–14 years and for those aged 15–19 years as a catch-up
strategy. It is also recommended for girls and boys with immune
deficiency conditions at ages 11–19, and for men who have sex
with men (MSM) up to the age of 26 [2]. The Ministry of Health
is considering widening the target groups to include boys as the
same ages of girls. Recently, the French National Authority forhuman
2 F. Dib et al. / Vaccine xxx (xxxx) xxxHealth (HAS) (an independent public scientific advisory body)
issued a favourable opinion on the widespread vaccination of boys
[3].
HPV vaccination in France relies on individual initiative,
requires parental authorization for those under 18 years, and is
prescribed and administered by medical doctors. It can also be
administered by nurses with a medical prescription. It is costly
and only partially (65%) reimbursed by the National Health Insur-
ance Fund, but those covered by a voluntary private health insur-
ance (more than 95% of the French population [4]) or by the
Subsidized Supplementary Health Insurance (‘‘Complémentaire
santé solidaire”/ CSS, granted for individuals whose income is
below a given ceiling) are fully reimbursed.
Twelve years after its introduction, HPV vaccine uptake in
France remains low, despite the extensive safety data accumulated
for this vaccine both nationally and internationally [5–8]. In 2018,
the estimated coverage rate for full (two-dose) HPV vaccination
was estimated at 23.7% in girls aged 16 years [9], well below the
objective of a 60% coverage for a two-dose vaccination set by the
National Cancer Control Plan (NCCP) 2014-2019 [10], and the cov-
erage reached in other European countries, which ranged from less
than 40% in Germany [11] to more than 85% in the United Kingdom
[12].
Addressing the challenge of improving HPV vaccine coverage
has been on the French government’s and public health agencies’
agenda since 2009. The second NCCP (2009–2013) aimed to
improve the uptake of HPV vaccination in 14-year-old girls
through the dissemination of appropriate information to the publicFig. 1. Conceptual framework of vaccine hesitancy and its de
Please cite this article as: F. Dib, P. Mayaud, O. Launay et al., Design and content
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screening using a cervical smear is still essential from the age of
25 onwards [13]. The current (third) NCCP 2014–2019 has aimed
to improve the uptake by increasing access to the vaccines in free
vaccination canters and by training healthcare professionals [10].
The reasons for the low HPV vaccination coverage in France
remain unclear [14–17]. There are conflicting data on the role of
socioeconomic status in vaccine uptake. In a large study using
the French National Health Insurance Database, the authors con-
cluded that no clear factor was identified as a vaccination determi-
nant; they suggested that complex associations between
socioeconomic and cultural factors could explain the low HPV vac-
cination coverage [15]. A European survey estimated that only 56%
of French parents intended to have their eligible daughters vacci-
nated (versus 67% in the United Kingdom) [18]. Furthermore, Ver-
ger and colleagues have found in a national panel of 1 712 general
practitioners (GPs) that 28% did not recommend HPV vaccines to
young girls [19], raising the issue of the negative influence of GPs
in vaccination decision-making.
The phenomenon known as ‘‘vaccine hesitancy” may partly
explain low HPV vaccine coverage in France. This term refers to a
complex, multifaceted phenomenon which occurs within a spec-
trum, from full and partial, to no vaccination. It is defined by the
World Health Organization (WHO) Strategic Advisory Group of
Experts (SAGE) vaccine hesitancy working group as ‘‘the delay in
acceptance or refusal of vaccines despite availability of vaccination
services (. . .) It is influenced by factors such as complacency, con-
venience and confidence”[20]. The prevalence of vaccine hesitancyterminants (Strategic Advisory Group of Experts model).
validation of a survey questionnaire assessing the determinants of human
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among French parents of adolescent girls aged 11–15 years; it is
particularly high among those with a higher education level [21].
Hesitancy and its adverse impacts on vaccine uptake rates have
been increasingly recognized by the WHO Strategic Advisory
Group of Experts (SAGE) on Immunization, leading to the publica-
tion in 2015 of a compendium of tools to measure vaccine hesi-
tancy [22]. These tools include a matrix of vaccine hesitancy
determinants organized in three main categories of survey ques-
tions: (i) contextual influences (e.g., cultural reasons, communica-
tion and social media), (ii) individual and group influences (e.g.,
immunization as a social norm versus not needed/harmful, distrust
in the vaccine and lack of perceived benefit of the vaccine), and (iii)
vaccine/vaccination-specific issues (e.g., vaccination schedule,
costs, and strength of the recommendation and/or attitude of
healthcare professionals). This tool is a useful comprehensive
approach to help diagnose major determinants of vaccine hesi-
tancy (Fig. 1). However, it was not designed as a survey-ready for-
mat for straightforward use in investigational activities, as
acknowledged by the Working Group [22]. Besides, the questions
displayed in this matrix address vaccines in general, not the HPV
vaccine in particular. This matrix was developed following a sys-
tematic review of existing research, the findings from an immu-
nization managers’ survey of vaccine hesitancy and expert
consultation [23].
The problem at the heart of the failed efforts to increase HPV
vaccination coverage may lie in the inability in identifying and
addressing the actual root causes of vaccine hesitancy and refusal.
It is, therefore, crucial to gain a greater understanding of the deter-
minants of HPV vaccine hesitancy in the French context so that tar-
geted interventions can be developed accordingly. There is
currently no specific tool to assess the determinants of HPV vaccine
hesitancy in France. This study aimed to develop and validate a
specific French Survey Questionnaire for the Determinants of
HPV Vaccine Hesitancy (FSQD-HPVH) to be later administered to
mothers of girls of eligible to HPV vaccination, using the SAGE
Working Group Determinants of Vaccine Hesitancy Matrix. Prelim-
inary validation was undertaken through assessment of the items
for content validity, i.e., the extent to which they are reflective of
the factors considered in the SAGE working group model [24].2. Materials and Methods
2.1. Study design
A two-round modified electronic Delphi methodology was
implemented using an instrument developed in the online
Research Electronic Data Capture (REDCap) survey system hosted
at the Pierre Louis Institute of Epidemiology and Public Health
(IPLESP), Paris Sorbonne University. REDCap is a secure, web-
based software platform designed to support data capture for
research studies [25]. We used a Delphi approach since it is a uni-
versally recognized scientific technique for tapping individual
judgments among experts from varying practices to build consen-
sus [26,27]. The Delphi methodology, developed by the Rand
Corporation, is a structured approach to group interaction using
self-completed questionnaires. Through an iterative process of
consultation rounds, the members of the group (the ‘‘experts”)
can reconsider their responses to the questionnaire after receiving
feedback about how their responses compare to those from the
rest of the group. The numbers of iterations of experts review
and consensus criteria were established before starting the study
[28,29]. Each panel member responded to the questionnaire indi-
vidually and independently, unbiased by the identity and opinions
of other panellists.Please cite this article as: F. Dib, P. Mayaud, O. Launay et al., Design and content
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The study scientific committee (comprised of FD, PC, and OL)
identified potential participants providing a range of expertise
and professional representation to ensure a broad knowledge base
on the issue of HPV vaccine hesitancy. Experts were selected if they
satisfied the following criteria: (1) had been engaged in clinical or
research work related to the field of vaccination or HPV for at least
3 years and, (2) were based in France or spoke French. There are no
hard rules for the number of Delphi panel participants, however, a
panel of 10 to 18 experts is generally recommended [30]. Thus, we
decided to invite at least twice the recommended number of pan-
ellists, allowing for a minimum 50% participation rate. In May
2019, we e-mailed invitation letters, including the information
on the aim of the study and a description of the Delphi study pro-
cedures to each potential panel member. Willing participants com-
pleted a brief form regarding their demographic and professional
data.
2.3. Survey instrument
Following an extensive literature review, the scientific commit-
tee drafted a list of items, covering the three main thematic cate-
gories ((i) contextual, (ii) individual and group and (iii)
vaccine/vaccination specific influences) and sub-categories of the
Working Group Determinants of Vaccine Hesitancy Matrix.
All of the matrix sub-categories were covered in our instru-
ment, except ‘‘Geographic barrier” (which may be best assessed
by objective measures such as indicators of health care supply in
the area of residence), ‘‘Mode of administration” (which is unlikely
to be a sizable concern in teenagers as opposed to babies and very
young children), ‘‘Risk/benefit of scientific and epidemiologic evi-
dence” and ‘‘Influential leaders, gatekeepers and anti-vaccination
lobbies” (whose related items could fit another matrix category;
for example, an item about past issues regarding another vaccine
could also fit the ‘‘Historical influences” category – a limit of the
matrix which has been described previously [31]). The survey
instrument was developed in French. In addition, 19 items were
taken from the HPV Attitudes and Beliefs Scale [32] (HABS) and
19 from the HPV General Knowledge and HPV Vaccination Knowl-
edge Scales [33], all of which have been validated in the French-
Canadian setting. When drawing from this instrument, we paid
particular attention to the need for transcultural adaptation, and
so we slightly reworded/reformulated 12 of the French-Canadian
items. One item on religion was taken from the Vaccine Confidence
ProjectTM [34]. Five items were taken from the Holistic Comple-
mentary and Alternative Medicine Questionnaire (HCAMQ) [35].
As there is no version of the HCAMQ validated in French, transla-
tion was performed. An initial translation (English into French)
was performed by two French native-speaking authors (FD and
PC). Back-translation (French to English) was then independently
performed by a third author (PM, non-English native speaker but
a fluent-speaking researcher who has been working in the UK for
almost three decades). The list of websites information was drawn
from the Vaccine Confidence ProjectTM data [36]. Items that did not
reach consensus and have not either attracted specific suggestion
for reformulation were recirculated without modification in the
wording.
2.4. Round 1
In June 2019, we launched the first round of our modified reac-
tive Delphi consultation by sending the structured questionnaire to
the expert panellists. Different from the traditional first stage of
Delphi procedure which requests participants to deliver new
thoughts on their own, we asked the experts panel to react tovalidation of a survey questionnaire assessing the determinants of human
ccine, https://doi.org/10.1016/j.vaccine.2020.07.027
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of our Delphi study [37]. The items included the set of response
options if the questions required modalities of responses other
than a numeric rating scale, i.e., yes/no or true/false/I do not know.
Experts were queried as to whether or not each of the items pro-
posed by the scientific committee was essential to assess a specific
factor on a 3-point Likert scale, in which 1 point meant ‘‘Essential”;
2 ‘‘Useful but not essential”, and 3 ‘‘Not necessary”. Besides,
experts were also invited to comment on items clarity/comprehen-
sion and suggest items potentially missing. As per the experts’
comments, the scientific committee reworded original items that
did not reach consensus and generated new ones.2.5. Round 2
Two months later, in August 2019, we e-emailed individualized
questionnaires to those experts who had returned Round 1
responses. Only items upon which consensus was not reached in
Round 1 were retained for re-assessment in Round 2 [38], thereby
allowing experts to focus on the questionable items and consider
changing their score (especially for those that have been reformu-
lated) [39] while reducing participant dropouts due to a burden-
some questionnaire. For each statement, participants were shown
their initial individual evaluation (which could be confirmed or
modified) and feedback from the Round 1: frequency distribution
of the ratings (thereby showing the general extent of agreement
in the experts’ opinions) and a summary of anonymous comments
made by the panel on Round 1. Participants were asked to re-rate
the items using the same method as in Round 1. The possibility to
amend previous scores, taking into consideration the overall pic-
ture is a fundamental part to reach consensus. Participants were
also asked the rate the newly generated items, in line with the sug-
gestions of Round 1. Participants were asked to return Round 2
responses within four weeks, with the help of e-mail reminders.
The survey instrument was finalised by excluding the questions
that did not reach consensus in Round 2.Table 1
Demographic and professional characteristics of the expert panel (n = 15).
N %
Gender
Female 10 (67)
Male 5 (33)
Discipline
Medical gynaecology 1 (6)
Obstetrics and gynaecology 2 (13)
Midwifery 1 (6)
General medicine 1 (6)
Infectious and tropical diseases 1 (6)
Virology/immunology 1 (6)
Public Health 2 (13)
Epidemiology 1 (6)
Anthropology 1 (6)
Sociology 2 (13)
Health and social psychology 1 (6)
Health psychology 1 (6)
Clinical practice
Yes 6 (40)
No 9 (60)
Practice site
Academic 11 (74)
Private practice 3 (20)
Public health agency 1 (6)
Years of experience
10 2 (13)
]10–20] 6 (40)
greater than20 7 (47)2.6. Data analysis
Lawshe’s Content-Validity Ratio (CVR) was computed after each
round to assess the consensus level for each statement. The CVR
measures agreement among raters regarding how a particular item
is essential to a particular construct. It is a function of the number
of participants and their ratings and ranges from 1 to 1. When
fewer than half of the participants rate the item as ‘‘essential,”
the CVR is negative, when half rate the item as ‘‘essential” and half
do not, the CVR is 0 and when all rate ‘‘essential,” the CVR is 1. The
formula for computing the CVR is CVR = (n-N/2)/(N/2), where
n = the number of participants rating the item as ‘‘essential” and
N = the total number of participants. Items with CVR values equal
to or greater to a certain threshold (determined according to the
number of respondents) were considered excellent in agreement
evaluation [40]. Traditionally, Lawshe’s method requires experts
to provide their ratings just once, and items are immediately dis-
carded if they fail to meet the minimum critical value. In this study,
we decided to subject the items that did not reach the minimum
critical value to further evaluation (whether as initially formulated
or reformulated as per the experts’ comments). This conservative
approach ensured no question would be missed out, given the
complexity and multifaceted nature of HPV vaccine hesitancy.
Demographic data of the experts’ panel, the percentages of
responses to each statement, and the CVR were analysed using
SAS (version 9.4, SAS Institute Inc., Cary North Carolina).Please cite this article as: F. Dib, P. Mayaud, O. Launay et al., Design and content
papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study, Va2.7. Ethics statement
In France, ethics approval is not required for research that does
not involve patients. The written invitations to the experts request-
ing them to participate in the study incorporated items conveying
confidentiality procedures, and the prerogative to erase their data
and thus revoke participation at any time. Data privacy and confi-
dentiality of all participants were ensured, although total anonym-
ity could not be achieved due to the need to directly e-mail
participants. However, participant identities were known only to
the main author, and participants were unaware of the identities
of the other panel members.
3. Results
3.1. Panel composition and response rates
Of the 40 potential panel members invited to participate in the
study, 18 (45%) responded and sent their demographic data. Of
them, 15 (6 health care professionals and 9 non-clinicians aca-
demics/researchers) sent back Rounds 1 and 2 questionnaires.
Panel members were all based in France, except two, based in
Canada and the UK (Table 1). For 15 participants, the minimum
critical value of the content validity ratio (CVR) was calculated to
be 0.6 (Round 1) at a = 5%.
3.2. Round 1
In Round 1, 83 items were evaluated by the expert panel, and
participants gave comments on 66 items (79%). A total of 35
(42%) items reached or exceeded the CVR minimum critical value
andwere set aside for inclusion in the final questionnaire. The anal-
ysis of the CVR of the individual items is shown in Table 2. Items
rated ‘‘essential” by all the experts pertained to ‘‘Knowledge/awar
eness”, ‘‘Communication and media environment”, ‘‘Immunisation
as a social norm versus not needed/harmful” and ‘‘The strength of
the recommendation and/or knowledge base and/or attitude of
healthcare professionals” factors.validation of a survey questionnaire assessing the determinants of human
ccine, https://doi.org/10.1016/j.vaccine.2020.07.027
Table 2
Measures of agreement and content validity ratio from Rounds 1 and 2.
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
Contextual factors
Communication and media
environment
I think that there is sufficient
communication on vaccination, in
general
15 60 0.20 I think there is enough official
information campaigns about
vaccination in general
– 15 67 0.33
I think that there is sufficient
communication on HPV vaccination
in particular
15 73 0.47 I think there is enough official
information campaigns about HPV
vaccination in particular
– 14 a 71 0.43
How did you hear about the HPV
vaccine? Recommendation of the
attending physician/
Recommendation of a paediatrician/
Recommendation of a gynaecologist/
Television/Social media/ Written
press/Family /Friends/School / Other
14a 100 1* – – – – –
A lot of information and testimonials
have been reported, which one (s)
have worried you the most? The HPV
vaccine can give multiple sclerosis /
The HPV vaccine is responsible for the
increase in the number of cancers of
cervical cancer/ The HPV contains
mercury, which is harmful to health/
The HPV vaccine contains aluminium,
which is harmful to health/Other/
None
15 71 0.43 Identical item with the addition of the
response mode ‘‘I have not heard
about it » for each proposal
– 14 a 71 0.43
Historical influences Since the H1N1 influenza scandal, I
have less confidence in the healthcare
system
15 73 0.47 Since the controversy over
vaccination against H1N1 flu, I have
less confidence in French vaccination
recommendations
– 15 87 0.73*
Since the controversy over the
hepatitis B vaccine, I have less
confidence in the healthcare system
15 80 0.60* – – – – –
The scandal of the Mediator** makes
me doubt the integrity of the
healthcare system
15 67 0.33 The Mediator’s case makes me doubt
the integrity of the health system
– 15 67 0.33
Religion/culture/gender/socio-
economic
With regard to religion, do you have a
regular religious practice/an
occasional religious practice/no
practice, but the feeling of belonging
to a religion/neither practice nor
feeling of belonging?
15 60 0.20 – – 15 53 0.07
(If practice religious/sense of
belonging) Is the HPV vaccine
compatible with your religious
beliefs? –
15 67 0.33 – – 15 67 0.33
I think that vaccinating girls against
HPV encourages them to have sex
15 93 0.87* – – – – –
The fact that the HPV vaccine protects
against a sexually transmitted
infection makes me hesitate to
vaccinate my daughter
15 53 0.07 I hesitate to get my daughter
vaccinated against the
papillomavirus because it is a
sexually transmitted infection
– 15 67 0.33
(continued on next page)
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Table 2 (continued)
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
It is hard to talk to my daughter about
her sexual health y
15 60 0.20 – – 15 87 0.73*
I am not comfortable discussing my
daughter’s sexual health with a
doctor/health care provider y
15 73 0.47 I feel uncomfortable discussing my
daughter’s sexual health with a
doctor or another health
professional
– 15 93 0.87*
Sex is not a subject I talk about with
my daughter y
15 53 0.07 Sexuality is a subject I approach with
difficulty with my daughter
– 15 73 0.57
I am not comfortable talking to my
daughter about the HPV vaccine y
15 53 0.07 I am uncomfortable talking to my
daughter about the HPV vaccine
– 15 73 0.57
I do not know how to approach the
topic of HPV vaccine with my
daughter y
15 73 0.47 I have difficulty in addressing the
subject of HPV vaccine with my
daughter
– 15 93 0.87*
Politics/policies I am favourable to the 11 vaccines
mandatory for children born since
January 1st, 2018
14 a 86 0.71* – – – – –
– – – – – Everyone should be able to
choose whether or not to do
vaccinate his/her children
15 93 0.87*
– – – – – Everyone should be able to
decide which vaccines are
necessary for his/her children
15 67 0.33
Perception of the
pharmaceutical industry
The pharmaceutical industry is
concerned above all by its financial
interests
15 60 0.20 The pharmaceutical industry is more
concerned about its financial
interests than by public health
– 15 67 0.33
The pharmaceutical industry follows
strict manufacturing procedures
15 80 0.60* – – – – –
The HPV vaccine is being pushed to
make money for pharmaceutical
companies y
15 73 0.47 The recommendation of the
papillomavirus mainly serves the
financial interests of the
pharmaceutical industry
– 15 73 0.57
– – – – – The pharmaceutical industry
follows rigorous procedures to
control the safety of vaccines
15 67 0.33
Individual and group factors
Personal, family and/or
community members’
experience
I happened to refuse a vaccine for my
daughter (or choose not to get her
vaccinated)
15 93 0.87* – – – – –
I happened to refuse a vaccine for
myself (or choose not to get
vaccinated)
15 87 0.73* – – – – –
I know a person who fell seriously ill
after getting vaccinated
15 87 0.73* – – – – –
I know someone who became
seriously ill because s/he was not
vaccinated
15 87 0.73* – – – – –
Personally, I have already had
abnormal pap smears for which
treatment was needed
(conization/surgery)
15 93 0.87* – – – – –
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Table 2 (continued)
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
Beliefs, attitudes about health
and prevention
Complementary medicine should be
subject to more scientific testing
before it can be accepted by
conventional doctors §
15 47 0.06 Alternative medicines (i.e. non-
conventional medicines, for example
phytotherapy, homeopathy,
naturopathy. . .) should be subjected
to more scientific studies before they
can be accepted by conventional
physicians.
– 15 27 0.46
Complementary medicine can be
dangerous in that it may prevent
people getting proper treatment §
15 33 0.33 Alternative medicines (i.e. non-
conventional medicines, for example
phytotherapy, homeopathy,
naturopathy. . .) may be dangerous
as they can prevent people from
obtaining/accessing appropriate
treatment
– 14a 28 0.43
Complementary medicine should
only be used as a last resort when
conventional medicine has nothing to
offer §
15 67 0.33 Alternative medicines should only
be used as a last resort when
conventional medicine has nothing
to offer
– 14a 43 0.14
It is worthwhile trying
complementary medicine before
going to the doctor §
15 40 0.20 It is interesting to try alternative
medicines (i.e. non-conventional
medicines, for example
phytotherapy, homeopathy,
naturopathy. . .) before going to the
doctor
– 14 a 36 0.29
Complementary medicine builds up
the body’s own defenses, so leading
to a permanent cure §
15 80 0.60* – – – – –
– – – – – Alternative medicines (i.e.non-
conventional medicines, for
example phytotherapy,
homeopathy, naturopathy. . .)
can replace some vaccines
15 73 0.57
– – – – – I prefer that my daughter
develops naturally defences
against papillomavirus rather
than by vaccination
15 80 0.60*
Knowledge/awareness Have you ever searched for
information on the HPV vaccine in the
past?
14 a 100 1* – – – – –
(If already researched information)
Cite the 3 most consulted sources of
information: Attending physician/
Other health professional/Internet/
Family/ Books/Print media/Other
15 87 0.73* – – – – –
(If used the internet) How did you use
the internet? I went to forums/I
visited blogs/I looked at social media/
I consulted news websites/Other
15 87 0.73* – – – – –
(If consulted information sites)
Which website? Santé Publique
France/ Vaccination info service/
15 73 0.47 (If consulted information sites)
Which website? Santé Publique
France /Vaccination info service/
– 15 80 0.60*
(continued on next page)
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Table 2 (continued)
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
Doctissimo, Allodocteur/Pourquoi
docteur/Infovac/ France Info/Le
Monde/Le Figaro/Alter Info/
Alternative Health/Initiative
citoyenne/Other
Doctissimo, Allodocteur/Pourquoi
docteur/Infovac/France Info / Le
Monde/Le Figaro/Alter Info/
Alternative Health/Initiative
citoyenne/ Mesvaccins.net/INCa/
other
(If has already searched for
information) After having had all this
information, were you able to take a
decision regarding the HPV
vaccination?
15 87 0.73* – – – – –
HPV can cause HIV/AIDS yy 15 53 0.07 – – 15 47 0.06
The HPV vaccine requires only one
dose yy
15 53 0.07 – – 15 40 0.20
The HPV vaccines offer protection
against all sexually transmitted
infections yy
15 67 0.33 – – 15 87 0.73*
The HPV vaccines are most effective if
given to people who’ve never had sex
yy
15 73 0.47 – – 15 87 0.73*
Someone who has had the HPV
vaccine cannot develop cervical
cancer yy
15 67 0.33 A person who has been vaccinated
against HPV can still develop
cervical cancer
– 15 80 0.60*
The HPV vaccines offer protection
against most cervical cancers yy
15 67 0.33 – – 15 73 0.57
The HPV vaccines offer protection
against genital warts yy
15 87 0.73*
Girls who have had the HPV vaccine
do not need a Pap test when they are
odler yy
15 71 0.33 Girls who have been vaccinated
against HPV need Pap test when they
are older
– 15 87 0.73*
The HPV vaccine protects (you) from
every type of HPV yy
15 53 0.07 – – 14 a 64 0.43
You can cure HPV by getting the HPV
vaccine yy
15 73 0.47 – – 15 80 0.60*
HPV is very rare yy 15 80 0.60* – – – – –
HPV always has visible signs or
symptoms yy
15 60 0.20 There are always signs or symptoms
visible in case of papillomavirus
infection
– 15 67 0.33
Men cannot get HPV yy 15 87 0.73* – – – – –
A person could have HPV for many
years without knowing it yy
15 86 0.60* – – – – –
Having sex at an early age increases
the risk of getting HPV yy
15 67 0.33 – – 14 a 78 0.57*
HPV can be transmitted through oral
sex yy
15 80 0.60* – – – – –
HPV can cause cancer of the penis yy 15 67 0.33 – – 15 73 0.57
HPV infections always lead to health
problems yy
14 a 43  0.14 – – 15 53 0.07
HPV can cause oral cancer yy 13b 70 0.36 – – 15 80 0.60*
– – – – HPV can cause anal cancer yy 15 60 0.28
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Table 2 (continued)
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
Health system and providers-
trust and personal
experience
Please indicate to what extent you
trust the following sources to tell the
truth about vaccinations:
pharmaceutical
industry/government/your attending
physician/physicians in general/
pharmacists/other health
professionals/scientific researchers /
mainstream media/alternative media
(media that convey information
alternatives to the commercial mass
media and state media, e.g. Agoravox,
Altlantic, and Alterinfo)
15 93 0.87* – – – – –
I know someone in my circle who has
already been victim of a medical error
15 53 0.07 – – 15 33 0.28
I consider that I have already been
victim of a medical error
15 53 0.07 – – 15 33 0.28
Risk/benefit (perceived,
heuristic)
Giving my daughter the HPV vaccine
would be like performing an
experiment on her y
15 27 0.46 – – 15 20 0.57
The HPV vaccine may lead to long-
term health problems y
15 80 0.60* – – 14 a 50 0
There has not been enough research
done on the HPV vaccine y
15 93 0.87* – – – – –
The HPV vaccine is unsafe y 15 80 0.60* – – – – –
The HPV vaccine has many benefits y 15 53 0.07 – – 14 a 50 0
The HPV vaccine will protect my
daughter’s sexual health y
15 74 0.46 Vaccinating my daughter against
HPV will help protect her against i
sexually transmitted infections
– 15 80 0.60*
The HPV vaccine is effective in
preventing HPV y
15 80 0.60* – – – – –
The HPV vaccine is effective in
preventing genital warts y
15 80 0.60* – – – – –
The HPV vaccine is effective in
preventing HPV-related cancers y
15 71 0.42 – 14 a 93 0.86*
– – – – – Without the HPV vaccine, my
daughter would be at risk of
getting HPV later in life y
15 53 0.07
– – – – – Without the HPV vaccine, my
daughter would be at risk of
getting genital wartsl later in
life y
15 53 0.07
– – – – – Without the HPV vaccine, my
daughter would be at risk of
getting an HPV related cancer
later in life y
15 67 0.33
– – – – – The use of a condom prevents
the transmission of HPV
infection
15 87 0.73*
– – – – – The pap smear is sufficient to
prevent cervical cancer
14 a 86 0.85*
(continued on next page)
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Table 2 (continued)
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
– – – – – HPV can be passed on during
sexual intercourse yy
15 67 0.33
– – – – – Having many sexual partners
increases the risk of getting
HPV yy
15 67 0.33
Immunisation as a social
norm vs. not needed/
harmful
My friends are getting their daughter
vaccinated with the HPV vaccine y
14 a 93 0.87* – – – – –
Most cgirls around my daughter ’s age
are getting vaccinated for HPV y
14 a 100 1* – – – – –
It is expected of me that I should
vaccinate my daughter against HPV y
14 a 57 0.14 – – 14 a 43 0.14
– – – – – Most of my friends think
vaccinating my daughter
against HPV is a good idea y
14 a 43 0.14
– – – – – Doctors/health care providers
believe vaccinating girls
against HPV is a good idea y
15 93 0.87*
– – – – – My family thinks it is a good
idea to vaccinate my -daughter
against HPV y
15 60 0.28
Vaccine/vaccination specific factors
Introduction of a new vaccine
or new formulation or a
newrecommendation for
an existing vaccine
The HPV vaccine is too new y 15 74 0.46 The HPV vaccine is too recent so we
can know if it’s safe and reliable
– 15 80 0.60*
Design of vaccination
program/Mode of delivery
It is complicated to vaccinate my
daughter against HPV because it
requires 3 steps: see the doctor for
the vaccine prescription, go buy the
vaccine at the pharmacy, and return
to the doctor for the vaccine injection
15 80 0.60* – – – – –
It would be easier to vaccinate my
daughter if the pharmacist could
perform the injection
15 67 0.33 – – 14a 71 0.43
It would be easier to vaccinate my
daughter if the doctor had vaccines at
his office for vaccinating my daughter
the same day
15 80 0.60* – – – – –
– – – – – It would be easier to get my
daughter vaccinated against
HPV if this vaccination was
carried out at school
(instruction: ask the question
in the past if the vaccine has
been administered)
15 73 0.57
Reliability and/or source of
supply of vaccine and/or
vaccination equipment
I am concerned about the quality of
the vaccines because they can be
manufactured elsewhere than in
Europe
15 60 0.20 – – 15 47 0.06
I trust the pharmacists to keep
vaccines cold as required
15 47 0.06 – – 15 40 0.20
I do not find it normal that some
vaccines are out of stock
15 67 0.33 – – 15 60 0.28
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Table 2 (continued)
Round 1 (n = 15) Round 2 (n = 15)
Factor Initial item N % agreement
for ‘‘essential”
Content
Validity
Ratio
Reformulated item Additional item n %
agreement
for
‘‘essential”
Content
Validity
Ratio
Vaccination schedule If the HPV vaccine was important, it
would have been made mandatory
14a 86 0.71* – – – – –
The HPV vaccine has not been made
mandatory because it is risky
14 a 73 0.47 – – 15 80 0.60*
I think my daughter is too young to
be vaccinated against HPV
15 87 0.73* – – – – –
Costs I think that the HPV vaccine is too
expensive for my budget
15 73 0.47 I think the HPV vaccine is too
expensive for me
15 73 0.47
The strength of the
recommendation and/or
knowledge base
and/or attitude of
healthcare professionals
Has a doctor or another health
professional ever recommended that
you vaccinate your daughter against
HPV?
15 100 1* – – – – –
Have you asked any questions to your
attending doctor about HPV
vaccines?
15 93 0.87* – – – – –
(If has already asked questions) Were
you satisfied with his/her answers?
15 87 0.73* – – – – –
– – – – – (If has already asked questions
of her doctor concerning
vaccination against HPV) Was
your attending physician
hesitant regarding this
vaccine?
15 100 1*
aCVR for 14 respondents = 0.57.
bCVR for 13 respondents = 0.54.
cWe replaced the term ‘‘other” used in the original instrument by ‘‘most”.
y Items from the HPV Attitudes and Beliefs Scale (19 items submitted in Round 1 and 6 items submitted in Round 2).
yy Items from the HPV General Knowledge and the HPV Vaccination Knowledge Scales (19 items submitted in Round 1 and 3 items submitted in Round 2).
§ Items from the Holistic Complementary and Alternative Medicine Questionnaire (5 items submitted in Round 1)
– Items from the Vaccine Confidence Project (1 item submitted in Round 1).
* Response over the predefined threshold according to Lawshe’s formula.
**Mediator was an antidiabetic drug given as a slimming agent, leading to national scandal in France.
Bold values indicate content validity ratio above the threshold.
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Fig. 2. Flow chart of the modified Delphi method for two survey rounds. *HABS: HPV Attitudes and Beliefs Scale (HABS). ** HCAMQ: Holistic Complementary and Alternative
Medicine Questionnaire.
12 F. Dib et al. / Vaccine xxx (xxxx) xxx3.3. Round 2
In Round 2, 66 items were submitted to the expert panel. Of
those, 48 were items that did not reach consensus at Round 1 and
were recirculated either as initially worded (n = 25, 52%) or after
rewording (n = 23, 48%), and 18 were new items. Among the new
items, 9 were drawn from existing instruments (one item about
‘‘Knowledge/awareness” drawn from the HPV General Knowledge
and HPV Vaccination Knowledge Scales [33], 3 items about ‘‘Immu-
nisation as a social norm vs. not needed harmful” drawn from the
HABS (32), and 5 items about ‘‘Risk/benefit (perceived/heuristic)”
drawn from the HABS (n = 3) and from the HPV General Knowledge
and HPV Vaccination Knowledge Scales (n = 2) [33]); the remaining
were developed by the scientific committee (Table 2, Fig. 2). In total,
consensus was reached on 22 items (33%). The analysis of the CVR
of the individual items is shown in Table 2.
The final version of the survey instrument will include 57 items
(Fig. 2 and Supplemental File 1): 10 items in the category ‘‘Contex-
tual influences”, 37 items in the category ‘‘Individual and group
influences”, and 10 items in the category ‘‘Vaccine/vaccination-spe
cific issues”.
4. Discussion
In this study, we developed a survey instrument specifically
intended to evaluate HPV vaccine hesitancy among mothers ofPlease cite this article as: F. Dib, P. Mayaud, O. Launay et al., Design and content
papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study, Vaage-vaccination daughters in France. Within two rounds of a reac-
tive Delphi methodology that took 12 weeks from preparation to
conclusion, we generated a pool of items and consulted a panel
of 15 experts who helped develop and validate a list of questions
that reflect the many factors identified in the SAGE Working Group
Determinants of Vaccine Hesitancy Matrix and that should now be
applied to a survey of HPV vaccination vaccine hesitancy among
mothers in France.
This study builds on the limited literature to date about how to
measure the determinants of HPV vaccine hesitancy. Before start-
ing this exercise, we had found only tools focusing on partial
aspects of the factors contributing to vaccine hesitancy, e.g., the
Carolina HPV immunization attitudes and beliefs scale (CHIAS)
[41] and HABS [32], but none looking at determinants comprehen-
sively. The domains covered by the FSQD-HPVH that the above-
mentioned tools do not include are essentially those that fall under
‘‘Contextual factors”, for example, ‘‘Historical influences”, ‘‘Politics/
policies” and ‘‘Communication and media environment”. The other
domains not covered by existing questionnaires include the
‘‘Strengths of the recommendations and/or knowledge base and/
or attitudes of healthcare professionals” and ‘‘Design of vaccination
program/mode of delivery”. This study is novel in considering
using the SAGE Working Group Determinants of Vaccine Hesitancy
Matrix. This matrix has been used to classify the data of the Annual
WHO/UNICEF JRF (which are collected globally across WHO Mem-
ber States to monitor vaccine hesitancy) [42], but not as a data col-validation of a survey questionnaire assessing the determinants of human
ccine, https://doi.org/10.1016/j.vaccine.2020.07.027
F. Dib et al. / Vaccine xxx (xxxx) xxx 13lection tool. We hope the current study will stimulate further use
of this matrix to investigate vaccine hesitancy related to other vac-
cines or settings.
We constructed a questionnaire with the most content-valid
items. It appeared that only 42% of the items were deemed repre-
sentative of the construct (factor) they intended to measure at
Round 1. This finding emphasizes the relevance of including the
perspectives of a multidisciplinary panel of experts. However,
some of the items could be selected after rewording (n = 8/23,
35%). Each factor is represented by at least one item, except ‘‘Reli-
ability and/or source of supply of vaccine and/or vaccination equip-
ment” and ‘‘Costs”, which ended up without any item.
The main strengths of our study include the composition of a
multidisciplinary and multi-stakeholder panel of experts and the
rigorousmultistage quantitative analysis of their responses. As vac-
cine hesitancy is a complex, multifaceted phenomenon, the prob-
lem needs to be examined in a multidisciplinary manner. An
excellent retention rate (100%) was achieved in Round 2, avoiding
the risk of response bias. However, some limitations need to be
acknowledged. First, the length of the final questionnaire might
be challenging from a practical point of view. In a subsequent study,
we aim to propose a shortened version based on factor analysis of
the data collected through this questionnaire. Second, the sample
size of the panel of experts was small, although it falls within the
range recommended in the literature, and the calculation of the
consensus criterion was weighted by the number of respondents.
Third, we only performed the a priori-planned two rounds of Delphi
survey. There is a delicate trade-off between the number of rounds
and the risk of attrition, and it turned out that no modification in
terms of rewording was required following Round 2, since the
experts did not suggest any reformulations for the items that did
not meet consensus. In addition, three factors (‘‘Communication
and media environment”, ‘‘Perception of the pharmaceutical indus-
try”, ‘‘Health system and providers-trust and personal experience”)
ended up with only one item. Although single-item measures for
each facet of multifaceted constructs have been suggested in the lit-
erature [43], these are often considered to compromise on reliabil-
ity. Finally, the questionnaire was designed to target only the
mothers as they often have the main decision-making power with
regard to the HPV vaccination [44–46]. Adaptation of the item ‘‘Per-
sonally, I have already had abnormal pap smears for which treat-
ment was needed (conization/surgery)” would be required it the
questionnaire is to be administered to fathers. Finally, the FSQD-
HPVH was designed to be administered to the French population,
with reference to the French health system and culture. However,
our approach could provide a reference for other settings. The
FSQD-HPVH has not yet been pilot-tested, but it is intended to aid
in the evaluation of HPV vaccine hesitancy in France through
administration to a large sample of mothers, which will, in turn,
allow further validation.5. Conclusion
In conclusion, 57 items of FSQD-HPVH with good content valid-
ity were developed in this study in preparation of a thorough eval-
uation of HPV vaccine hesitancy in France. Unlike other existing
tools, the FSQD-HPVH is the first to comprehensively consider all
factors that may influence HPV vaccine hesitancy, the first step
towards an evidence-based approach to curbing the low HPV vac-
cination rates in France.6. Author’s contributions
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